ORPHA:832
Succinyl-CoA:3-oxoacid CoA transferase deficiency
Also known as: OXCT1 deficiency · SCOT deficiency · Succinyl-CoA acetoacetate transferase deficiency · Succinyl-CoA:3-ketoacid CoA transferase deficiency
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
204
67.7th percentile
Trials
0
Interventional, condition-specific
Researchers
1,191
Distinct authors in sample
Gene link
OXCT1
Definitive
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, genetic disorder in ketone body utilization characterized by severe, potentially fatal intermittent episodes of ketoacidosis.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0009492
- MeSH:C537527
- OMIM:245050
- UMLS:C0342792
Additional Mondo synonyms (4)
Succinyl CoA:3-oxoacid CoA transferase deficiency · succinyl-CoA acetoacetate transferase deficiency · succinyl-CoA:3-ketoacid CoA transferase deficiency · succinyl-CoA:3-oxoacid CoA transferase deficiency
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — OXCT1
- LiteraturePresent
204 matched papers (107 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (OXCT1).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
204
204 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
204 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
107 in the last 10 years · medium confidence · 67.7th percentile (publications denominator)
Phrase hits: 204 · MeSH hits: 0
Who's working on it?
1,191
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Fukao T22 papers · 2017
Department of Pediatrics, Gifu University School of Medicine, Gifu, Gifu, 500-8076, Japan. toshi-gif@umin.ac.jp
Papers in Europe PMC - 02Kondo N15 papers · 2013Papers in Europe PMC
- 03Crawford PA7 papers · 2023
Center for Metabolic Origins of Disease, Sanford Burnham Prebys Medical Discovery Institute, Orlando, FL 32827, USA. Electronic address: pcrawford@sbpdiscovery.org.
Papers in Europe PMC - 04Chen Y6 papers · 2025
National Heart Lung and Blood Institute, NIH, 31 Center Drive, Building 31, Bethesda, MD 20892, USA.
Papers in Europe PMC - 05Sass JO6 papers · 2021
Bioanalytics & Biochemistry, Department of Natural Sciences, Bonn-Rhein-Sieg University of Applied Sciences, von-Liebig-Str. 20, 53359, Rheinbach, Germany. joern.oliver.sass@h-brs.de.
Papers in Europe PMC - 06Mitchell GA5 papers · 2001Papers in Europe PMC
- 07Shintaku H5 papers · 2004Papers in Europe PMC
- 08Song XQ5 papers · 2000
Department of Pediatrics, Gifu University School of Medicine, Japan.
Papers in Europe PMC - 09Hirayama K4 papers · 1998Papers in Europe PMC
- 10Kassovska-Bratinova S4 papers · 2000
Service de Génétique Médicale, Hôpital Sainte-Justine, Montréal, Québec, Canada.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Succinyl-CoA:3-oxoacid CoA transferase deficiency" OR "OXCT1 deficiency" OR "SCOT deficiency" OR "Succinyl-CoA acetoacetate transferase deficiency" OR "Succinyl-CoA:3-ketoacid CoA transferase deficiency" OR "Succinyl CoA:3-oxoacid CoA transferase deficiency"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Succinyl-CoA:3-oxoacid CoA transferase deficiency" OR "OXCT1 deficiency" OR "SCOT deficiency" OR "Succinyl-CoA acetoacetate transferase deficiency" OR "Succinyl-CoA:3-ketoacid CoA transferase deficiency" OR "Succinyl CoA:3-oxoacid CoA transferase deficiency" OR "OXCT1"
Recall-expansion terms: OXCT1
Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (204) is high for prevalence class "<1 / 1 000 000" — confidence capped at medium
Ingested 2026-07-26T15:35:28.685Z